lipolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
ambassador to Israel Matt Gonzalez (1987), Green Party San Francisco mayoral candidate and independent 2008 candidate for vice president running with Ralph Nader Tim Kelly (1989), 74th mayor of Chattanooga, Tennessee Julie Menin (1989), former chairperson of Manhattan Community Board 1 and former commissioner of the New York City Department of Consumer Affairs Dave Hunt (1990), 65th speaker of the Oregon House of Representatives and majority leader 2007–2009 Michael Leiter (1991), principal deputy director of the National Counterterrorism Center; former deputy chief of staff for the Office of the Director of National Intelligence Melissa Mark-Viverito (1991), speaker of the New York City Council Benjamin Lawsky (1992), attorney and New York City's first superintendent of financial services Peter Hatch (1992), commissioner of the New York City Department of Consumer and Worker Protection Eric Garcetti (1992), member of the Los Angeles City Council and current mayor of Los Angeles, nominee to be U.S. ambassador to India Rohit Aggarwala (1993), commissioner of the New York City Department of Environmental Protection Matt Brown (1993), secretary of state of Rhode Island 2003–2007; co-founder of non-partisan group Global Zero Alan D.
=== Evidence for a mechanism === There has been no discovery of a single mechanism or process by which all cells undergo electrotaxis. However, multiple explanations have been investigated, resulting in a considerable body of evidence and a limited understanding of how cells migrate using electric fields. Electrotaxis is thought to operate based on changes in Ca2+ concentration produced by direct-current electric fields (dcEFs) due to the fact that exposure to dcEFs) can cause concentration changes in excess of 1 millimolar. Additionally, calcium channel inhibition using Co2+ or D600 was observed to prevent electrotaxis in most cases. Cells that exhibit electrotaxis undergo an influx of Ca2+ ions on the anodal side of the cell, and simultaneous decrease in concentration on that cathodal side. This rearrangement is thought to create "push-pull" forces that induce net movement in the cathodal direction. However, this process would be more complicated in cells with intercellular calcium stores or voltage-gated calcium channels. In addition, voltage-gated sodium channels, protein kinases, growth factors, surface charge, and protein electrophoresis have been observed to have a role in electrotaxis. However, there is no knowledge of a sensor molecule used specifically for electrotaxis. The exact role and function of these and other cellular components in electrotaxis is not fully understood and is the basis of ongoing research.
=== Eggsquis === Eggsquis is a midscale chain of restaurants in Quebec and Ontario. As of 2018, there are 39 outlets, which are primarily in Quebec. It specializes in egg dishes, from bacon and eggs to omelettes. The first Eggsquis restaurant was opened by Elias Stergiou in Sherbrooke, in 1995. In 2010, the owners of the restaurant chain Chez Cora took Eggsquis to court, claiming that some of the dishes at its Mascouche location had been copied from Cora's, including the names of the dishes.
=== Desalination === Treatment must also take into account the type of water the wood was found in. Waterlogged wood recovered from marine environments may contain high levels of salts, which must be removed from the waterlogged wood to prevent further damage on drying. This can be done by a desalination process. Desalination is often completed in bath changes using clean water. Sometimes disinfectants (fungicides or algaecides) are added to prevent the development of damaging organisms. However, the most commonly used and recommended because of its lesser toxicity is a mixture of boric acid and borax. The desalination process takes a long period of time and is necessary that the water is changed until the concentration of excreted of soluble salts reach its maximum.
Sources: en.wikipedia.org
=== Labour Party organiser === Galloway joined the Labour Party Young Socialists aged 13, having falsely claimed to have been 15, and was still a teenager when he became secretary of the Dundee Labour Party. Galloway became vice-chairman of the Labour Party in the City of Dundee and a member of the Scottish Executive Committee in 1975. On 5 May 1977, he contested his first election campaign in the Scottish district elections, but failed to hold the safe Labour Gillburn ward in Dundee, being defeated by the independent Bunty Turley. He became the secretary organiser of the Dundee Labour Party in 1977, and at 26, was the youngest ever chairman of the Scottish Labour Party in March 1981, a post he held for a year, after holding the vice-chairman post over the previous year. After a trip to Beirut, Lebanon, during 1977, Galloway became a supporter of Palestine, stating during his libel case against The Daily Telegraph in 2004 that "barely a week after my return I made a pledge, in the Tavern Bar in Dundee's Hawkhill District, to devote the rest of my life to the Palestinian and Arab cause." He supported Dundee City Council when it flew the Palestinian flag over the City Chambers building, and was involved in the twinning of Dundee with the Palestinian West Bank town of Nablus in 1980. In late 1981, in an interview for the Scottish Marxist, Galloway supported the affiliation of the Communist Party of Great Britain (CPGB) to the Labour Party, in the same way as the Fabian Society does.
=== Red yeast rice and statin drugs === In the late 1970s, researchers in the United States and Japan were isolating lovastatin from Aspergillus and monacolins from Monascus, the latter being the same fungus used to make red yeast rice (RYR) when cultured under carefully controlled conditions. Chemical analysis soon showed that lovastatin and monacolin K are identical chemical compounds. The two isolations, documentations, and patent applications occurred months apart. Lovastatin became the patented, prescription drug Mevacor. Red yeast rice went on to become a non-prescription dietary supplement in the United States and other countries. Lovastatin and other prescription statin drugs inhibit cholesterol synthesis by blocking action of the enzyme HMG-CoA reductase. As a consequence, circulating total cholesterol and LDL-cholesterol are lowered by 24–49% depending on the statin and dose. Different strains of Monascus fungus will produce different amounts of monacolins. The 'Went' strain of Monascus purpureus (purpureus=dark red in Latin), when properly fermented and processed, will yield a dried red yeast rice powder that is approximately 0.4% monacolins, of which roughly half will be monacolin K (chemically identical to lovastatin).
Hyperthymesiacs also have difficulties letting go of difficult events or traumatic memories, which can stay with them for life. Joey DeGrandis, who was featured in the magazine Time said, "I do tend to dwell on things longer than the average person, and when something painful does happen, like a break-up or the loss of a family member, I don't forget those feelings." Cases of hyperthymesia have forced many people to re-evaluate what is meant by "healthy" memory: "it isn't just about retaining the significant stuff. Far more important is being able to forget the rest."
In so doing Jesus had relied upon Christ, a synonym for Truth, Science and God, a power that Quimby believed all human beings could access. Quimby referred to this idea, in February 1863, as "Christian science," a phrase he used only once in writing. He wrote:
==== Idiopathic scrotal calcinosis ==== Idiopathic scrotal calcinosis is a cutaneous condition characterized by calcification of the skin resulting from the deposition of calcium and phosphorus occurring on the scrotum. However, the levels of calcium and phosphate in the blood are normal. Idiopathic scrotal calcinosis typically affects young males, with an onset between adolescence and early adulthood. The scrotal calcinosis appears, without any symptoms, as yellowish nodules that range in size from 1 mm to several centimeters.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.